EEaka Ελληνική Εταιρία Αλλεργιολογίας και Κλινικής Ανοσιολογίας
1) N Cabañes, JM Igea, B de la Hoz .
On behalf of the Committee of Latex Allergy of the Spanish Society of Allergology and Clinical Immunology (SEAIC).
Latex Allergy: Position Paper.
J Investig Allergol Clin Immunol 2012; Vol. 22(5): 313-330
Abstract.
Correct management of latex allergy is essential to ensure adequate care of patients who are allergic to latex, which is ubiquitous in the health care setting. In this Position Paper, the Latex Committee of the Spanish Society of Allergology and Clinical Immunology provides guidelines for the management of latex allergy.
Η πρόσβαση στο άρθρο είναι ελεύθερη :
2) Eustachio Nettis ; Pantalea Delle Donne; Elisabetta Di Leo; Paola Fantini, MD; Giovanni Passalacqua; Roberto Bernardini; Giorgio Walter Canonica; Antonio Ferrannini; and Angelo Vacca.
Latex immunotherapy: state of the art.
Ann Allergy Asthma Immunol. (Προδημοσίευση).
http://www.annallergy.org/article/S1081-1206%2812%2900502-9/abstract
Abstract.
Objective
Latex allergy remains a significant problem, expecially among certain professional categories, and specific immunotherapy has been suggested as a suitable therapeutic option. The objective of the this article is to review the available literature on clinical trials of specific immunotherapy in latex allergy.
Data Sources
Literature databases (PubMed, Embase, Google Scholar) were searched for latex immunotherapy clinical trials.
Study Selections
Clinical trials (either open or randomized controlled) using subcutaneous or sublingual immunotherapy with latex extracts were selected. Only articles published in English in peer-reviewed journals were considered. Case reports quoted in the clinical trials were also described, when pertinent.
Results
Eleven clinical trials (3 with subcutaneous and 8 with sublingual immunotherapy) were identified. Two of the 3 randomized trials of subcutaneous immunotherapy reported some benefit in adults but a remarkable occurrence of side effects. Concerning sublingual immunotherapy (SLIT), there were 6 randomized placebo-controlled (1 in children), 1 randomized open, and 1 open trials. All but 1 trial reported positive results, and the safety profile was overall superior to injection immunotherapy. The overall quality of the study was moderate, and the number of subjects studied was low.
Conclusion
Although guidelines do not consider allergy to latex as an accepted indication to desensitization, SLIT can be offered, in addition to symptomatic treatment, to selected patients, when avoidance measures are not feasible or effective.